Cargando…

Cognitive and Behavior Deficits in Parkinson’s Disease with Alteration of FDG-PET Irrespective of Age

Significant progress has been made in our understanding of the neurobiology of Parkinson’s disease (PD). Post-mortem studies are an important step and could help to comprehend not only the progression of motor symptoms, but also the involvement of other clinical domains, including cognition, behavio...

Descripción completa

Detalles Bibliográficos
Autores principales: Lauretani, Fulvio, Ruffini, Livia, Testa, Crescenzo, Salvi, Marco, Scarlattei, Mara, Baldari, Giorgio, Zucchini, Irene, Lorenzi, Beatrice, Cattabiani, Chiara, Maggio, Marcello
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8628799/
https://www.ncbi.nlm.nih.gov/pubmed/34842741
http://dx.doi.org/10.3390/geriatrics6040110
_version_ 1784607073902788608
author Lauretani, Fulvio
Ruffini, Livia
Testa, Crescenzo
Salvi, Marco
Scarlattei, Mara
Baldari, Giorgio
Zucchini, Irene
Lorenzi, Beatrice
Cattabiani, Chiara
Maggio, Marcello
author_facet Lauretani, Fulvio
Ruffini, Livia
Testa, Crescenzo
Salvi, Marco
Scarlattei, Mara
Baldari, Giorgio
Zucchini, Irene
Lorenzi, Beatrice
Cattabiani, Chiara
Maggio, Marcello
author_sort Lauretani, Fulvio
collection PubMed
description Significant progress has been made in our understanding of the neurobiology of Parkinson’s disease (PD). Post-mortem studies are an important step and could help to comprehend not only the progression of motor symptoms, but also the involvement of other clinical domains, including cognition, behavior and impulse control disorders (ICDs). The correlation of neuropathological extension of the disease with the clinical stages remains challenging. Molecular imaging, including positron emission tomography (PET) and single photon computed tomography (SPECT), could allow for bridging the gap by providing in vivo evidence of disease extension. In the last decade, we have observed a plethora of reports describing improvements in the sensitivity of neuroimaging techniques. These data contribute to increasing the accuracy of PD diagnosis, differentiating PD from other causes of parkinsonism and also obtaining a surrogate marker of disease progression. FDG-PET has been used to measure cerebral metabolic rates of glucose, a proxy for neuronal activity, in PD. Many studies have shown that this technique could be used in early PD, where reduced metabolic activity correlates with disease progression and could predict histopathological diagnosis. The aim of this work is to report two particular cases of PD in which the assessment of brain metabolic activity (from FDG-PET) has been combined with clinical aspects of non-motor symptoms. Integration of information on neuropsychological and metabolic imaging allows us to improve the treatment of PD patients irrespective of age.
format Online
Article
Text
id pubmed-8628799
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-86287992021-11-30 Cognitive and Behavior Deficits in Parkinson’s Disease with Alteration of FDG-PET Irrespective of Age Lauretani, Fulvio Ruffini, Livia Testa, Crescenzo Salvi, Marco Scarlattei, Mara Baldari, Giorgio Zucchini, Irene Lorenzi, Beatrice Cattabiani, Chiara Maggio, Marcello Geriatrics (Basel) Case Report Significant progress has been made in our understanding of the neurobiology of Parkinson’s disease (PD). Post-mortem studies are an important step and could help to comprehend not only the progression of motor symptoms, but also the involvement of other clinical domains, including cognition, behavior and impulse control disorders (ICDs). The correlation of neuropathological extension of the disease with the clinical stages remains challenging. Molecular imaging, including positron emission tomography (PET) and single photon computed tomography (SPECT), could allow for bridging the gap by providing in vivo evidence of disease extension. In the last decade, we have observed a plethora of reports describing improvements in the sensitivity of neuroimaging techniques. These data contribute to increasing the accuracy of PD diagnosis, differentiating PD from other causes of parkinsonism and also obtaining a surrogate marker of disease progression. FDG-PET has been used to measure cerebral metabolic rates of glucose, a proxy for neuronal activity, in PD. Many studies have shown that this technique could be used in early PD, where reduced metabolic activity correlates with disease progression and could predict histopathological diagnosis. The aim of this work is to report two particular cases of PD in which the assessment of brain metabolic activity (from FDG-PET) has been combined with clinical aspects of non-motor symptoms. Integration of information on neuropsychological and metabolic imaging allows us to improve the treatment of PD patients irrespective of age. MDPI 2021-11-10 /pmc/articles/PMC8628799/ /pubmed/34842741 http://dx.doi.org/10.3390/geriatrics6040110 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Case Report
Lauretani, Fulvio
Ruffini, Livia
Testa, Crescenzo
Salvi, Marco
Scarlattei, Mara
Baldari, Giorgio
Zucchini, Irene
Lorenzi, Beatrice
Cattabiani, Chiara
Maggio, Marcello
Cognitive and Behavior Deficits in Parkinson’s Disease with Alteration of FDG-PET Irrespective of Age
title Cognitive and Behavior Deficits in Parkinson’s Disease with Alteration of FDG-PET Irrespective of Age
title_full Cognitive and Behavior Deficits in Parkinson’s Disease with Alteration of FDG-PET Irrespective of Age
title_fullStr Cognitive and Behavior Deficits in Parkinson’s Disease with Alteration of FDG-PET Irrespective of Age
title_full_unstemmed Cognitive and Behavior Deficits in Parkinson’s Disease with Alteration of FDG-PET Irrespective of Age
title_short Cognitive and Behavior Deficits in Parkinson’s Disease with Alteration of FDG-PET Irrespective of Age
title_sort cognitive and behavior deficits in parkinson’s disease with alteration of fdg-pet irrespective of age
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8628799/
https://www.ncbi.nlm.nih.gov/pubmed/34842741
http://dx.doi.org/10.3390/geriatrics6040110
work_keys_str_mv AT lauretanifulvio cognitiveandbehaviordeficitsinparkinsonsdiseasewithalterationoffdgpetirrespectiveofage
AT ruffinilivia cognitiveandbehaviordeficitsinparkinsonsdiseasewithalterationoffdgpetirrespectiveofage
AT testacrescenzo cognitiveandbehaviordeficitsinparkinsonsdiseasewithalterationoffdgpetirrespectiveofage
AT salvimarco cognitiveandbehaviordeficitsinparkinsonsdiseasewithalterationoffdgpetirrespectiveofage
AT scarlatteimara cognitiveandbehaviordeficitsinparkinsonsdiseasewithalterationoffdgpetirrespectiveofage
AT baldarigiorgio cognitiveandbehaviordeficitsinparkinsonsdiseasewithalterationoffdgpetirrespectiveofage
AT zucchiniirene cognitiveandbehaviordeficitsinparkinsonsdiseasewithalterationoffdgpetirrespectiveofage
AT lorenzibeatrice cognitiveandbehaviordeficitsinparkinsonsdiseasewithalterationoffdgpetirrespectiveofage
AT cattabianichiara cognitiveandbehaviordeficitsinparkinsonsdiseasewithalterationoffdgpetirrespectiveofage
AT maggiomarcello cognitiveandbehaviordeficitsinparkinsonsdiseasewithalterationoffdgpetirrespectiveofage